Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T01:24:42.407Z Has data issue: false hasContentIssue false
  • English
  • Français

Choice of neuroleptics in epilepsy

Published online by Cambridge University Press:  02 January 2018

Harry McConnell ,
Denise Duncan  and
David Taylor
Harry McConnell
Affiliation:
Institute of Psychiatry
Denise Duncan
Affiliation:
Maudsley Hospital, Denmark Hill, London SE5 8AZ
David Taylor*
Affiliation:
Maudsley Hospital, Denmark Hill, London SE5 8AZ
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The decision to use a neuroleptic in people with epilepsy (PWE) depends on the nature of the psychosis being treated. In some cases a neuroleptic is not required and an adjustment of the antiepileptic drug therapy may be all that is necessary. Antiepileptic drug therapy itself can cause psychosis and this, as well as other aetiologies, should be considered. The choice of neuroleptic in PWE depends on: the nature of the patient's psychosis, including the temporal relationship with seizures and/or any relationship to antiepileptic drug therapy; the epileptogenicity of the neuroleptic; antiepileptic drugs; the efficacy of the neuroleptic; and individual tolerability of side-effects.

Type
Drug Information Quarterly
Information
Psychiatric Bulletin , Volume 21 , Issue 10 , October 1997 , pp. 642 - 645
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1997 The Royal College of Psychiatrists

References

Arana, G. W., Goff, D. C., Friedman, H., et al (1986) Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? American Journal of Psychiatry, 143, 650–651 Google Scholar
Fast, D. K., Jones, B. D., Kusalic, M., et al (1986) Effect of carbamazepine on neuroleptic plasma levels and efficacy. American Journal of Psychiatry, 143, 117–118.Google Scholar
Fenwick, P. (1995) Psychiatric disorder and epilepsy. In Epilepsy (eds Hopkins, A., Shorvon, S. & Cascino, G.), pp. 453–502. London: Chapman and Hall Medical.Google Scholar
Itil, T. M. & Soldatos, C. (1980) Epileptogenic side effects of psychotropic drugs. Journal of the American Medical Association, 244, 1460–1463.Google Scholar
Izmeth, M., Khan, S., Kumarajeewa, D., et al (1988) Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients. Pharmatherapeutica, 5, 217–227.Google Scholar
Keepers, G. A. (1990) Neuroleptic malignant syndrome associated with withdrawal from carbamazepine (letter). American Journal of Psychiatry, 147, 12.Google Scholar
Ketter, T. A., Post, R. M. & Worthington, K. (1991) Principles of clinically important drug interactions with carbamazepine, part II. Journal of Clinical Psychopharmacology, 11, 306–312.Google Scholar
Larkin, C. (1983) Epileptogenic effect of pimozide. American Journal of Psychiatry, 140, 372–373.Google Scholar
Logothetis, J. (1967) Spontaneous epileptic seizures and EEG changes in the course of phenothiazine therapy. Neurology, 17, 869–877.Google Scholar
Markowitz, J. C. & Brown, R. P. (1987) Seizures with neuroleptics and antidepressants. General Hospital Psychiatry, 9, 135–141.Google Scholar
Marks, R. C. & Luchins, D. L. (1991) Antipsychotic medications and seizures. Psychiatric Medicine, 9, 37–52.Google Scholar
McConnell, H. W. & Duncan, D. A. (1997) The treatment of psychiatric co-morbidity in epilepsy. In Epilepsy and Psychiatric Co-Morbidity: Basic Mechanisms, Diagnosis and Treatment (eds McConnell, H. W. & Snyder, P. J.), in press. Washington. DC: American Psychiatric Press.Google Scholar
Miller, D. D. (1991) Effect of phenytoin on plasma clozapine concentrations in two patients. Journal of Clinical Psychiatry, 52, 23–25.Google Scholar
Oliver, A. P., Luchins, D. J. & Wyatt, R. J. (1982) Neuroleptic-induced seizures. Archives of General Psychiatry, 39, 206–209.CrossRefGoogle ScholarPubMed
Pacia, S. V. & Devinsky, O. (1994) Clozapine-related seizures. Neurology, 44, 2247–2249.CrossRefGoogle ScholarPubMed
Remick, R. & Fine, S. (1979) Antipsychotic drugs and seizures. Journal of Clinical Psychiatry, 40, 78–80.Google Scholar
Satoh, H., Nakanishi, H., Shirakawa, K., et al (1987) Comparative study of tiapride and neuroleptics with anti-dopamine activity on convulsive seizure in mice. Japan Journal of Pharmacology, 43, 27–32.Google Scholar
Tiihonen, J., Vartiainen, H. & Hakola, P. (1995) Carbamazapine induced changes in plasma levels of neuroleptics. Pharmacopsychiatry, 28, 26–28.Google Scholar
Toone, B. K. & Fenton, G. W. (1977) Epileptic seizures induced by psychotropic drugs. Psychological Medicine, 7, 265–270.Google Scholar
Toth, P. & Frankenburg, F. R. (1994) Clozapine and seizures–a review. Canadian Journal of Psychiatry, 39, 236–238.Google Scholar
Trimble, M. R. (1985) The psychoses of epilepsy and their treatment. In The Psychopharmacology of Epilepsy, (ed. Trimble, M. R.), pp. 83–94. Chichester: John Wiley and Sons.Google Scholar
Trimble, M. R. (1991) Treatment of epileptic psychosis. In The Psychosis of Epilepsy, (ed. Trimble, M. R.), pp. 150–165. New York: Raven Press.Google Scholar
Whitworth, A. B. & Fleischhacker, W. W. (1995) Adverse effects of antipsychotic drugs. International Clinical Psychopharmacology, 9 (suppl. 5). 21–27.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.